Bayer Healthcare LLC

Bayer Schering Pharma Ag

Psioxus Therapeutics Limited

Bayer Intellectual Property Gmbh

Peter Kretschmer

Terry Hermiston

Uwe Gritzan

Maxine Bauzon

Richard N Harkins

Fang Jin

Chandra Patel

Lilley Leong

Peter Droescher

Paul Szymanski

Konstantin Levitsky

This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids.

Variant factor VIII polypeptides and methods of their production and use

The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.

Generation of replication competent viruses for therapeutic use

Growing community of inventors

San Francisco, CA, United States of America

Peter Kretschmer